Lumos Pharma, Inc. (NASDAQ:LUMO) reported Q4 EPS of ($3.71), $2.78 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $114.33 thousand.
Lumos Pharma, Inc. (NASDAQ:LUMO) reported Q4 EPS of ($3.71), $2.78 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $1.52 million versus the consensus estimate of $114.33 thousand.